WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206191
CAS#: 1338545-07-5 (HCl)
Description: OTS964 is a potent and selective TOPK inhibitor with potential anticancer activity. OTS964 inhibits TOPK kinase activity with high affinity and selectivity. Similar to the knockdown effect of TOPK small interfering RNAs (siRNAs), this inhibitor causes a cytokinesis defect and the subsequent apoptosis of cancer cells in vitro as well as in xenograft models of human lung cancer. Although administration of the free compound induced hematopoietic adverse reactions (leukocytopenia associated with thrombocytosis), the drug delivered in a liposomal formulation effectively caused complete regression of transplanted tumors without showing any adverse reactions in mice. ( Sci Transl Med. 2014 Oct 22;6(259):259ra145. )
MedKoo Cat#: 206191
Name: OTS964 HCl
CAS#: 1338545-07-5 (HCl)
Chemical Formula: 23H25ClN2O2S
Molecular Weight: 428.975
Elemental Analysis: C, 64.40; H, 5.87; Cl, 8.26; N, 6.53; O, 7.46; S, 7.47
OTS964 HCl, purity > 98%, is in stock. The same day shipping after order received.
Related CAS #: 1338542-14-5 (free base) 1338545-07-5 (HCl)
Synonym: OTS964; OTS964; OTS 964; OTS964 HCl; OTS964 hydrochloride
IUPAC/Chemical Name: (R)-9-(4-(1-(dimethylamino)propan-2-yl)phenyl)-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one hydrochloride
InChi Key: YHPWOYBWUWSJDW-UQKRIMTDSA-N
InChi Code: InChI=1S/C23H24N2O2S.ClH/c1-13-11-18(26)19(16-7-5-15(6-8-16)14(2)12-25(3)4)20-17-9-10-28-22(17)23(27)24-21(13)20;/h5-11,14,26H,12H2,1-4H3,(H,24,27);1H/t14-;/m0./s1
SMILES Code: [H]Cl.O=C1NC2=C(C(C3=CC=C([C@@H](C)CN(C)C)C=C3)=C(O)C=C2C)C4=C1SC=C4
The following data is based on the product molecular weight 428.975 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Novel molecule targets cytokinesis. Cancer Discov. 2015 Jan;5(1):OF8. doi: 10.1158/2159-8290.CD-NB2014-170. Epub 2014 Nov 13. PubMed PMID: 25583820.
2: Matsuo Y, Park JH, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, Nakamura Y. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145. doi: 10.1126/scitranslmed.3010277. PubMed PMID: 25338756.